Haemonetics Corporation (HAE)vsStryker Corporation (SYK)
HAE
Haemonetics Corporation
$55.93
-1.29%
HEALTHCARE · Cap: $2.65B
SYK
Stryker Corporation
$327.65
-0.26%
HEALTHCARE · Cap: $125.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 1805% more annual revenue ($25.12B vs $1.32B). HAE leads profitability with a 13.3% profit margin vs 12.9%. HAE appears more attractively valued with a PEG of 0.90. HAE earns a higher WallStSmart Score of 67/100 (B-).
HAE
Strong Buy67
out of 100
Grade: B-
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+66.2%
Fair Value
$169.88
Current Price
$55.93
$113.95 discount
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 21.0%
Earnings expanding 28.4% YoY
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
Distress zone — elevated risk
Elevated debt levels
Revenue declined 2.7%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HAE
The strongest argument for HAE centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.90 suggests the stock is reasonably priced for its growth.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : HAE
The primary concerns for HAE are Altman Z-Score, Debt/Equity, Revenue Growth.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
HAE profiles as a declining stock while SYK is a value play — different risk/reward profiles.
SYK carries more volatility with a beta of 0.87 — expect wider price swings.
SYK is growing revenue faster at 11.4% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Bottom Line
HAE scores higher overall (67/100 vs 65/100). SYK offers better value entry with a 16.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?